<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572114</url>
  </required_header>
  <id_info>
    <org_study_id>18/0075</org_study_id>
    <secondary_id>IRAS ID 243171</secondary_id>
    <nct_id>NCT03572114</nct_id>
  </id_info>
  <brief_title>Imaging Neuromelanin and Iron in Dystonia/Parkinsonism</brief_title>
  <official_title>Imaging Neuromelanin and Iron in Dystonia/Parkinsonism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To generate pilot data to investigate the potential to use in vivo iron- and
      neuromelanin-quantification as imaging tools for the diagnostic evaluation of movement
      disorders with predominant dystonia / parkinsonism. To this end we are planning to compare
      the MR imaging neuromelanin and iron-pattern and content in midbrain, striatum and further
      brain structures in clinically similar entities and respective, sex- and age-matched healthy
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Iron- or Neuromelanin-sensitive MR-imaging has not been consistently applied to the study of
      syndromes presenting with predominant dystonia/parkinsonism yet. We are planning to study the
      following groups, as they can often be very difficult to be distinguished from PD and in
      particular young-onset PD, on clinical grounds only:

        -  Dopa-responsive dystonia (DRD) can present similar to young-onset PD, but carries a
           completely different prognosis, necessitating different treatment requirements due to
           fundamentally different underlying physiology.

        -  Sporadic and Inherited dystonias (i.e. due to TorsinA (DYT1) and other gene mutations)
           often present with dystonia, particularly affecting the leg, which is clinically
           indistinguishable from young-onset PD.

        -  Young-onset PD, i.e. PD presenting with motor symptoms before 45 years of age, caused by
           a familiar gene mutation (PARKIN, Pink, DJ-1, PLA2G6, FBX07, ATP13A2, VPS13C, RAB39B,
           Lubag), often presents with predominant dystonia, particularly with leg-onset.

        -  NBIAs present with dystonia/parkinsonism: while basal ganglia iron accumulation is a
           known hallmark feature of the condition [3], the characteristics of neuromelanin
           regulation are unknown.

        -  Mitochondrial disease presenting with dystonia / parkinsonism (such as for example Leigh
           syndrome due to mutations in the Surf-1 gene or mutations m.3243A&gt;G or POLG) [4]

        -  Respective age- and sex-matched healthy controls This study is designed to produce pilot
           data on these disease entities. By potentially accelerating the diagnostic process and
           identification of disease entities, neurologists might be able to deliver more selective
           and dedicated treatment.

      Furthermore, combining Neuromelanin- and iron-specific imaging will offer the possibility to
      study the condition- specific dynamics of iron homeostasis in these rare conditions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>neuromelanin content</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>absolute amount of neuromelanin in midbrain, striatum and other areas of the brain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neuromelanin association</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>correlate neuromelanin quantification with demographic and clinical details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>iron association</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>correlate neuromelanin quantification with demographic and clinical details</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron content</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>absolute amount of iron in midbrain, striatum and other areas of the brain</description>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sporadic Dystonia</condition>
  <condition>Dystonia, Familial</condition>
  <condition>Parkinson Disease, Juvenile</condition>
  <condition>Neurodegeneration With Brain Iron Accumulation 5</condition>
  <condition>Mitochondrial Diseases</condition>
  <arm_group>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mitochondrial disease</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>3Tesla MRI</intervention_name>
    <description>A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content
Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).
1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)
conventional FLAIR sequence</description>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <arm_group_label>mitochondrial disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Burke-Fahn-Marsden Dystonia Rating scale</intervention_name>
    <description>internationally standardized examination/quantification of dystonia</description>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <arm_group_label>mitochondrial disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MDS-United Parkinsons Disease Rating Scale, Part III</intervention_name>
    <description>most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society</description>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <arm_group_label>mitochondrial disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Beck Depression Inventory</intervention_name>
    <description>internationally standardized examination to quantify traits of anxiety and depression</description>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <arm_group_label>mitochondrial disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MoCA: Montreal Cognitive Assessment:</intervention_name>
    <description>internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism</description>
    <arm_group_label>Familial Dystonia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Neurodegeneration with brain iron acc.</arm_group_label>
    <arm_group_label>Parkinson´s disease, juvenile</arm_group_label>
    <arm_group_label>Sporadic Dystonia</arm_group_label>
    <arm_group_label>mitochondrial disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from the National Hospital of Neurology, Queen Square, movement disorder
        outpatient clinic;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of parkinsonism and/or dystonia due to

          -  dopa-responsive dystonia

          -  sporadic or inherited/genetic dystonia

          -  young-onset Parkinson`s disease

          -  NBIA

          -  Mitochondrial disease

               -  OR healthy controls

               -  18 to 60 years of age

               -  able to give informed consent

        Exclusion Criteria:

          -  Inability to tolerate 35min in an MRI machine

          -  Participated in a clinical drug trial up to 28 days before inclusion into the present
             study

          -  Contra-indications to 3T MRI on MRI safety grounds, such as presence of
             contra-indicated medical implants, as according to the established routine operating
             procedures for clinical MRI in the Lysholm Department of Neuroradiology at the
             National Hospital for Neurology and Neurosurgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhatia P Kailash, MD, DM, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL, Institute of Neurology, Sobell Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastian R Schreglmann, MD</last_name>
    <phone>0203448 8604</phone>
    <email>skgtsrs@ucl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bhatia P Kailash, MD, DM, FRCP</last_name>
    <phone>0203448 4252</phone>
    <email>k.bhatia@ucl.ac.uk</email>
  </overall_contact_backup>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>June 27, 2018</last_update_submitted>
  <last_update_submitted_qc>June 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

